AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$TWST

Laponis Adam sold $273K of TWST

Laponis Adam (Chief Financial Officer) sold 1,965 shares of Twist Bioscience Corp (TWST) at $139.07 ($0.27M total) on 2026-08-21.

Original reporting
SEC EDGAR · Laponis Adam
Published Aug 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Insider sale is small; likely limited market reaction.

02

Market read

Minor insider transaction with low trading relevance.

03

What to watch

Possible upcoming corporate actions not disclosed.

Relevance 4/10Novelty 4/10Timing: same-day filing

Background

Form 4 filing by Twist Bioscience CFO indicating a modest share sale.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

CFO Adam Laponis sold 1,965 shares for $273,264, reducing his stake to 108,633 shares.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

Sale amount is small relative to total holdings and market cap; unlikely to move price.

Market effects

Sector

No significant effect on biotech sector.

Regional

None.

Global

Minimal.

Counterpoint

What could challenge this read

Potential undervaluation if insider believes stock is overvalued.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech company specializing in DNA synthesis.

  • Executive
    Adam Laponis

    Chief Financial Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min